General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | 0 | N/A | N/A | N/A |
2024-04-01 | 2023-12 | 0 | N/A | N/A | N/A |
2024-01-16 | 2023-09 | 0 | -0.07 | N/A | N/A |
2023-05-15 | 2023-03 | -0.3 | -0.45 | -0.15 | -50.00% |
2023-03-27 | 2022-12 | -0.9 | -1.5 | -0.6 | -66.67% |
2022-11-07 | 2022-09 | -1.8 | -0.9 | 0.9 | 50.00% |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-04 | AJJARAPU SURENDRA K | Chief Executive Officer | 0.00 | Stock Award(Grant) |
2020-04-13 | DOSS HOWARD A | Chief Financial Officer | 12.50K | Stock Award(Grant) |
2022-08-31 | FELL DONALD G. | Director | 75.66K | Stock Award(Grant) |
2022-12-12 | HUFFMAN JANET | Chief Financial Officer | 71.55K | Stock Award(Grant) |
2021-05-26 | JENNINGS CHRISTINE L. | Director | 10.91K | Stock Award(Grant) |
2022-12-29 | NEWELL A. JEFFREY | Director | 79.06K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Morgan Stanley | 13.87K | 180.96K | 1.11% |
2023-06-29 | Barclays Plc | 4.80K | 62.65K | 0.38% |
2023-06-29 | Tower Research Capital LLC (TRC) | 2.13K | 27.86K | 0.17% |
2023-06-29 | JP Morgan Chase & Company | 884.00 | 11.54K | 0.07% |
2023-06-29 | UBS Group AG | 900.00 | 11.75K | 0.07% |
2023-09-29 | Ronald Blue Trust, Inc. | 357.00 | 2.51K | 0.03% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-05-30 | Fidelity Extended Market Index Fund | 24.19K | 101.59K | 1.94% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 15.39K | 64.65K | 1.23% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.64K | 34.49K | 0.21% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.93K | 8.11K | 0.15% |
Dividend | Date |
---|---|
8 | 2024-03-25 |
Split | Date |
---|---|
1 : 15 | 2023-06-22 |
I called Merril and Schwab about the payout divided tomorrow.Merrill says if you receive the dividend,you will have to hold the stock until Monday and the stock price will be adjusted $8 less on Monday.If you sell the stock after the 18th you may receive the cash but there is a possibility that they take the money from your account.Any one who buys the stock between now and tomorrow will loose $8 per share.I will advise to get out between now and tomorrow.That stock doesnโt work the headache
Took a small position, slap and hold
$MEDS The swell of public offerings in 2020-2021 increased the number of active nasdaq symbols from 3400 to over 5500, diluting market with questionable value, leading to the massive bear market weโve had. IMHO every single public company SEC filing should begin with a disclaimer of any existing shelf offering outstanding(this should be the very first mention in any filing, especially small caps, AND specifically what it means potentially). MEDS has an existing shelf of $100million. The reverse split reduces the number of shares outstanding, but does NOT reduce the dollar amount of a potential $100million dilutive secondary offering.
$MEDS there were no shorts here. This is all retail hopium. Itโs just not smart money to put your trust in a company like this on Friday after hours news, after a reverse split, with a shelf offering worth 900% of its market value on the table, in a risen interest rate enlviroment.
$MEDS perfect timing. A Friday after hours pump. Iโve seen so many. You have an existing shelf to fulfill. $100million. Your existing shares are 862,000. Youโre now under Nasdaq requirement of 35$million total market cap guidelines. You think of a scenario where you could actually achieve this, to stay listed, and liquid. Which is to pump news, then exercise the $100 million shelf offering,
With a $100,000,000 shelf on an 861,000 share outstanding, would equate to .00861$ per share. Just facts. No opinion.
$MEDS there are no shorts, this attempt is all retail. nobody intelligent shorts a stock with less than a million shares outstanding. Shorts have banked already. Crazy to buy $10 million company with an existing $100m shelf imho.
$MEDS (no position/no interest). Per the filings and the timing, Friday after hours, well, read between the lines.
$MEDS $100 million shelf registration exists. Just FYI, search โโshelfโ in https://www.sec.gov/Archives/edgar/data/1382574/000149315223017524/form10-q.htm
$MEDS I got suckers In last month and got out luckily today.
I averaged Down From $10. so if you got suckered in today and it drops to $4 like it did on me go back and look at past price history to see it will hopefully spike again to get you out. Good luck.
$MEDS nibbled on some here!
History $IBIO made money in all the pandemics, share price in pandemics was between 15$and 55$, big conference is coming, $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak.The spread of disease slowed and was forgotten about so the company SP went down all the way to pennies because there hasnโt been any major viruses since 2014. Now look where weโre at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come.
$MEDS gapping premarket
Most shares bought above $8 AH last night. This will take off